AbbVie Inc (ABBV) Stock Price, Trades & News

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.13
Equity-to-Asset	-0.05
Debt-to-Equity	-10.95
Debt-to-EBITDA	4.31
Interest Coverage	7.16
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.27	Distress Grey Safe
Beneish M-Score	-2.68	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	1.8
	3-Year EBITDA Growth Rate	-9.9
	3-Year EPS without NRI Growth Rate	-10.1
	3-Year FCF Growth Rate	-9.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	20.88
	Future 3-5Y Total Revenue Growth Rate Estimate	8.63

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	43.28
	9-Day RSI	56.22
	14-Day RSI	60.34
	3-1 Month Momentum %	8.18
	6-1 Month Momentum %	2.21
	12-1 Month Momentum %	15.36

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.8
	Quick Ratio	0.68
	Cash Ratio	0.22
	Days Inventory	96.79
	Days Sales Outstanding	73.15
	Days Payable	64.77

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.73
	Dividend Payout Ratio	0.65
	3-Year Dividend Growth Rate	5.2
	Forward Dividend Yield %	2.82
	5-Year Yield-on-Cost %	3.76
	Shareholder Yield %	2.99

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	70.68
	Operating Margin %	33.18
	Net Margin %	5.79
	EBITDA Margin %	26.94
	FCF Margin %	31.81
	OCF Margin %	33.79
	ROE %	Neg. Equity
	ROA %	2.68
	ROIC %	11.24
	3-Year ROIIC %	355.44
	ROC (Joel Greenblatt) %	162.62
	ROCE %	9.32
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	8

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	122.21
	Forward PE Ratio	17.45
	PE Ratio without NRI	24.35
	Shiller PE Ratio	52.9
	Price-to-Owner-Earnings	49.2
	PS Ratio	6.98
	Price-to-Free-Cash-Flow	22.03
	Price-to-Operating-Cash-Flow	20.71
	EV-to-EBIT	56.48
	EV-to-Forward-EBIT	19.71
	EV-to-EBITDA	29.66
	EV-to-Forward-EBITDA	15.51
	EV-to-Revenue	7.99
	EV-to-Forward-Revenue	7.5
	EV-to-FCF	25.12
	Price-to-GF-Value	1.17
	Price-to-Projected-FCF	2.43
	Price-to-Median-PS-Value	1.56
	Earnings Yield (Greenblatt) %	1.77
	FCF Yield %	4.56
	Forward Rate of Return (Yacktman) %	-1.96

Financials (Next Earnings Date:2026-07-31)

Annual Quarterly TTM

ABBV's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NYSE:ABBV

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

AbbVie Inc Executives

Details

GF Value™: $212.14

ABBV

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Medium warning signs with ABBV. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	62,819
	EPS (TTM) ($)	2.03
	Beta	0.0613
	3-Year Sharpe Ratio	0.86
	3-Year Sortino Ratio	1.54
	Volatility %	23.04
	14-Day RSI	60.34
	14-Day ATR ($)	6.616738
	20-Day SMA ($)	240.4325
	12-1 Month Momentum %	15.36
	52-Week Range ($)	184.63 - 261.635
	Shares Outstanding (Mil)	1,766.79

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

AbbVie Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

AbbVie Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-10-30 08:00	In 112 days
Third quarter earnings results for 2026	2026-10-30	In 111 days
Second quarter earnings conference call for 2026	2026-07-31 08:00	In 21 days
Second quarter earnings results for 2026	2026-07-31	In 20 days
USD 1.730000 Cash Dividend	2026-07-15	In 4 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 09:40	223.07 (-1.62%)
Bank of America Securities Healthcare Conference	2026-05-13 13:20	207.86 (+1.60%)
General meeting for 2026	2026-05-08 09:00	202.71 (-1.08%)
First quarter earnings conference call for 2026	2026-04-29 08:00	197.69 (-0.49%)
First quarter earnings results for 2026	2026-04-29	197.69 (-0.49%)

Show

Entries

AbbVie Inc Frequently Asked Questions

What is AbbVie Inc(ABBV)'s stock price today?

The current price of ABBV is $248.08. The 52 week high of ABBV is $261.64 and 52 week low is $184.63.

When is next earnings date of AbbVie Inc(ABBV)?

The next earnings date of AbbVie Inc(ABBV) is 2026-07-31.

Does AbbVie Inc(ABBV) pay dividends? If so, how much?

The Dividend Yield % of AbbVie Inc(ABBV) is 2.73% (As of Today), Highest Dividend Payout Ratio of AbbVie Inc(ABBV) was 0.66. The lowest was 0.41. And the median was 0.47. The Forward Dividend Yield % of AbbVie Inc(ABBV) is 2.82%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on NYSE:ABBV

No articles.

Press Release

	Subject	Date
	AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	2026-07-06
	AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	2026-06-29
	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata	2026-06-29
	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo	2026-06-29
	SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	2026-06-26
	AbbVie to Host Second-Quarter 2026 Earnings Conference Call	2026-06-26
	BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026	2026-06-24
	Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patien	2026-06-23
	AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection	2026-06-23
	AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis	2026-06-23

10/Page

Articles on AbbVie Inc

ABBV

AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100

59 minutes ago

ABBV

One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

1 day ago

ABBV

A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It

3 days ago

ABBV

AbbVie (ABBV) Updates 2026 Earnings Guidance

4 days ago

ABBV

AbbVie (ABBV) Adjusted EPS Guidance for Q2 Signals Slight Underperformance

4 days ago

Headlines

Jul 10, 2026

ClearBridge International Growth Strategy: Adds ABB, BUD; exits SAP, Wuxi AppTec in Q2

Seeking Alpha • 11:26am

Jul 07, 2026

AbbVie, Genmab granted EU label expansion for Tepkinly in follicular lymphoma

Seeking Alpha • 11:38am

Jul 06, 2026

AbbVie revises guidance; expects Q2 EPS to include unfavorable impact of $0.17

Seeking Alpha • 3:44pm

Jul 02, 2026

Big Pharma gains as U.S. weighs cutting 340B drug discounts

Seeking Alpha • 10:54am

Jun 30, 2026

AbbVie shares fell after six-session winning streak

Seeking Alpha • 3:09pm

Bristol, Merck, AbbVie face House committee probe over China trials

Seeking Alpha • 1:52pm

Jun 29, 2026

AbbVie touts phase 3 results for Epkinly in 2L large B-cell lymphoma

Seeking Alpha • 5:28pm

Jun 26, 2026

AbbVie's Skyrizi gains pediatric psoriatic disease indication

Seeking Alpha • 5:05pm

Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms

Seeking Alpha • 11:22am

Jun 25, 2026

Record-setting healthcare M&A activity to extend through H2: PwC

Seeking Alpha • 12:59pm

Jun 24, 2026

Spyre falls after $2M insider sale

Seeking Alpha • 9:39am

Jun 23, 2026

AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret

Seeking Alpha • 6:34am

AbbVie's Skyrizi wins EU approval for pediatric plaque psoriasis

Seeking Alpha • 4:01am

Jun 22, 2026

Midday Need to Know: AbbVie to buy Apogee, Micron partners with Anthropic & more

Seeking Alpha • 11:54am

Apogee jumps 52% on $10.9B AbbVie buyout deal

Seeking Alpha • 6:07am

Apogee soars on AbbVie deal report; analysts bullish

Seeking Alpha • 3:46am

Jun 20, 2026

AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics

Seeking Alpha • 6:56am

Jun 18, 2026

AbbVie declares $1.73 dividend

Seeking Alpha • 3:09pm

Jun 16, 2026

AbbVie gains approval of Juvederm injectable for neck wrinkles

Seeking Alpha • 9:31am

Jun 12, 2026

AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients

Benzinga • 9:30am

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

Benzinga • 6:30am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.